Double-blind, Placebo Controlled, Randomized Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BP1.5375 After Single Oral Administrations Ranging From 0.5 mg to 100 mg in Healthy Male Subjects (Part 1) Followed by the Assessment of the Effect of 3 Single Different BP1.5375 Oral Doses on Polysomnography in Comparison to 50 mg Diphenhydramine and Placebo in Healthy Male Subjects (Part 2).
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 发起方
- Bioprojet
- 入组人数
- 48
- 试验地点
- 1
- 主要终点
- Single Ascending Dose - safety and tolerability (Part 1)
研究概览
简要总结
Phase I Single Ascending Dose (Part 1), phase IIa Proof Of Concept (Part 2)
详细描述
This is a single center, Double-blind, placebo controlled, randomized study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of BP1.5375 after single oral administrations ranging in healthy male subjects (Part 1) followed by the assessment of the effect of 3 single different BP1.5375 oral doses on polysomnography in comparison to 50 mg diphenhydramine and placebo in healthy male subjects (Part 2).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Signed informed consent prior to any study-mandated procedure.
- •Healthy male subjects aged between 18 and 45 years (inclusive).
- •Subjects with a body weight of at least 50 kg and a body mass index (BMI) between 18.0 and 28.0 kg/m2 (both inclusive).
- •Healthy subjects, based on history, physical examination, complete laboratory evaluation, and 12-lead ECG.
- •Normal arterial blood pressure (BP) and pulse rate or, if abnormal, considered not clinically significant by the investigator. Normal BP to be [100-140] mmHg systolic and [45-90] mmHg diastolic. Normal pulse rate to be [40-90] bpm after 5 minutes rest in lying position.
- •Ability to communicate well with the investigator in the local language, and to understand and comply with the requirements of the study.
排除标准
- •Subject with a history of cardiovascular, pulmonary, gastro-intestinal, hepatic, renal, metabolic, haematological, neurological, psychiatric, systemic, or infectious disease, or any other condition which, in the opinion of the investigator, would jeopardize the safety of the subject, or impact the validity of the study results.
- •Previous history of fainting, collapse, syncope, orthostatic hypotension, or vasovagal reactions.
- •Haematology, clinical chemistry, and urinalysis results deviating from the normal range to a clinically relevant extent at screening.
- •Clinically significant findings on physical examination at screening.
- •12-lead electrocardiogram (ECG) with clinically relevant abnormalities in supine position at screening.
- •Positive results from urine drug screen at screening.
- •Veins unsuitable for i.v. puncture on either arm (e.g., veins that are difficult to locate, access or puncture, or veins with a tendency for rupture during or after puncture).
- •Treatment with any prescribed medications (including vaccines) or over-the-counter (OTC) medications (including herbal medicines such as St John's Wort) within 2 weeks prior to the (first) scheduled administration of study drug, except paracetamol (maximum 1 g/day).
- •Treatment with another investigational drug within 3 months prior to screening or having participated in more than four investigational drug studies within 1 year prior to screening.
- •History or clinical evidence of alcoholism or drug abuse within the 3-year period prior to screening.
- •History or clinical evidence of any disease, and/or existence of any surgical or medical condition, which might interfere with the absorption, distribution, metabolism or excretion of the study drugs.
- •Have undergone surgery or have donated an amount equal or more than 500 mL blood, or 300 mL of plasma, within 3 months prior to screening.
- •Positive results from any of the hepatitis serology tests (HBsAg, anti-HCV), at screening.
- •Positive results from the HIV 1 or/and 2 serology at screening.
- •History of allergy to diphenhydramine or antihistaminic drugs.
- •Smoking more than 5 cigarettes per day.
研究组 & 干预措施
BP1.5375
Single oral administration ranging from 0.5 mg to 100 mg
干预措施: BP1.5375 suspension (Drug)
BP1.5375
Single oral administration ranging from 0.5 mg to 100 mg
干预措施: Diphenhydramine (Drug)
BP1.5375
Single oral administration ranging from 0.5 mg to 100 mg
干预措施: Placebo (Drug)
Diphenhydramine
Single oral dose of diphenhydramine 50mg
干预措施: BP1.5375 suspension (Drug)
Diphenhydramine
Single oral dose of diphenhydramine 50mg
干预措施: Diphenhydramine (Drug)
Diphenhydramine
Single oral dose of diphenhydramine 50mg
干预措施: Placebo (Drug)
Placebo
Single oral dose
干预措施: BP1.5375 suspension (Drug)
Placebo
Single oral dose
干预措施: Diphenhydramine (Drug)
Placebo
Single oral dose
干预措施: Placebo (Drug)
结局指标
主要结局
Single Ascending Dose - safety and tolerability (Part 1)
时间窗: Study period and follow up visit will be no more than 5 weeks
To determine the clinical and biological safety and tolerability of BP1.5375 after an oral increasing single dose administration BP1.5375. * Physical examination : at screening and Follow-Up; a directed physical examination pre-dose and 24 hours post-dose, * Vital signs : at screening, on day -2, on day 1 pre-dose then 0.5, 1, 1.5, 2, 3, 4, 8, 12 and 24 hours post dose and FU, * Body temperature : at screening, on day -2, on day 1 pre-dose, then 24 hours post-dose and FU, * Standard 12 lead ECG recording : at screening, on day -2, on day 1 pre-dose, then 0.5, 1, 2, 3, 4, 8, 12 and 24 hours post-dose and FU, * Clinical laboratory tests: at screening, on day1 pre-dose, then 24 hours post-dose and FU, * 48-hour 12 leads continuous ECG Holter recording from day -1 morning until dosing and from dosing until the morning of day 2.
Proof of Concept - effect on polysomnography (Part 2)
时间窗: Study period and follow up visit will be no more than 9 weeks
To determine whether an BP1.5375 single oral dose induced an effect on polysomnography in healthy male subjects compared to diphenhydramine 50 mg and matching placebo. Safety and tolerability : Monitoring for the occurrence of AEs, changes in physical examination, vital signs (body temperature, lying and standing blood pressure and heart rate), ECG, and clinical laboratory tests. Assessments will be performed at the following time points : * Physical examination: at screening, on days 1 and FU, * Vital signs: at screening, on days 1 and 2 and FU, * Body temperature: at screening and FU, * Standard 12 lead ECG recording : at screening, on days 1 and 2 morning and FU, * Clinical laboratory tests : at screening, on days 1 and 2 and FU.
次要结局
未报告次要终点